Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | BLVRB | P30043 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757322 | 0.90 | HDAC6 (0.57) | HDAC6MAOABLVRBNPC1RAB9A | |
| SCHEMBL29629404 | 0.87 | HDAC6 (0.65) | HDAC6NPC1RAB9AHDAC4HDAC1 | |
| SCHEMBL29625980 | 0.87 | HDAC6 (0.65) | HDAC6NPC1RAB9AHDAC4HDAC1 | |
| SCHEMBL60207 | 0.86 | NPC1 (0.58) | HDAC6MAOABLVRBNPC1RAB9A | |
| SCHEMBL18824382 | 0.85 | HDAC6 (0.59) | HDAC6L3MBTL1HDAC4HDAC1HDAC8 | |
| SCHEMBL28499323 | 0.84 | HDAC6 (0.51) | HDAC6HDAC4HDAC1HDAC8HDAC7 | |
| SCHEMBL14645472 | 0.82 | HDAC4 (0.69) | HDAC6HDAC4HDAC8 | |
| SCHEMBL15632595 | 0.81 | NPC1 (0.67) | HDAC6MAOABLVRBNPC1RAB9A | |
| SCHEMBL29176862 | 0.81 | HDAC6 (0.52) | HDAC6HDAC4HDAC1HDAC8HDAC7 | |
| SCHEMBL60654 | 0.81 | NPC1 (0.63) | HDAC6MAOABLVRBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246956-A1 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| CN-115197207-B | Tetrahydro-gamma-carboline derivatives, pharmaceutical composition and application thereof | 上海交通大学 | 2024-03-22 | — | — | CN | disclosed |
| EP-4333842-A1 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022235565-A1 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-115197207-A | Tetrahydro-gamma-carboline derivatives, and pharmaceutical composition and application thereof | 上海交通大学 | 2022-10-18 | — | — | CN | disclosed |
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | GLAXOSMITHKLINE LLC | 2020-08-27 | — | — | US | disclosed |
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | GLAXOSMITHKLINE LLC | 2020-08-27 | — | — | US | disclosed |
| EP-3393458-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GlaxoSmithKline LLC (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112838-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112838-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2013006408-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | HDAC7, HDAC8, HDAC5 | HDAC6 9/4885MAOA 2330/4885BLVRB 1824/4885 |
| US-20240246956-A1 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | HDAC4, HDAC1, HDAC7 | HDAC6 9/4885MAOA 1786/4885BLVRB 2374/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | HDAC6 1763/4885MAOA 516/4885BLVRB 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.